Vaccinia Prostate Specific Antigen Vaccine

Known as: Prostate Specific Antigen Expressing Vaccinia Virus Vaccine, VPSA, rV-PSA Vaccine 
A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific… (More)
National Institutes of Health

Related topics

Related topics

10 relations
Cytotoxic T-LymphocytesGene Expression RegulationProstate-Specific AntigenRecombinant Vaccinia-Prostate Specific Antigen
(More)

Narrower (1)

PROSTVAC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
IMPORTANCE We previously showed that detection of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
PURPOSE The highly attenuated strain of vaccinia virus, modified vaccinia Ankara (MVA), encoding the tumor antigen 5T4 (termed… (More)
  • figure 1
  • table 2
  • figure 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
BACKGROUND Prostate-specific antigen (PSA) level is typically used as a dichotomous test for prostate cancer, resulting in… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
PURPOSE A phase II clinical trial was conducted to evaluate the feasibility and tolerability of a prime/boost vaccine strategy… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
BACKGROUND The relationship between prostate-specific antigen (PSA)-defined recurrence and prostate cancer-specific mortality… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
Recent studies of human immunodeficiency virus type 1 (HIV-1) infection in humans and of simian immunodeficiency virus (SIV) in… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
BACKGROUND A Phase I trial of recombinant vaccinia prostate specific antigen (rV-PSA) in patients with advanced metastatic… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
A recombinant vaccinia virus encoding human prostate-specific antigen (rV-PSA) was administered as three consecutive monthly… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Transient dominant selection of recombinant vaccinia viruses.
A general method for constructing and selecting recombinant vaccinia viruses with insertions, deletions, or mutations in any gene… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1987
Highly Cited
1987
HIV-specific cytotoxic T lymphocytes in seropositive individuals
Virus-specific cytotoxic T lymphocytes (CTL) which kill virus-infected cells are thought to be a major host defence against viral… (More)
Is this relevant?